Tecon Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2018

Location

Suzhou Jiangsu China

Primary Industry

Biotechnology

About

Founded in 2018 and based in Suzhou, China, Tecon is a biopharmaceutical company that focuses on the development of veterinary biological products. The predecessor of the company was the veterinary drug and biological products division of Tiankang Bio. In 2020, it launched a live gene-deleted vaccine for brucellosis. Tecon has 16 veterinary drug GMP production lines and 20 national new veterinary drug certificates. The company's main products include foot-and-mouth disease vaccine, live brucellosis vaccine, swine fever virus E2 protein recombinant baculovirus inactivated vaccine and anthrax series vaccines. Foot-and-mouth disease bivalent inactivated vaccine can only resist the challenge of the vaccine strain and can resist the challenge of other heterologous strains belonging to different genotypes from the vaccine strain in genetic taxonomy.

Current Investors

China Capital Management, Shenzhen Capital Real Estate Fund, Finnova Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Pharmaceutical Research & Development

Company Stage

Early Stage

Total Amount Raised

Subscriber access only

Employee Data

Want to see the Employee Count?

Request a demo for full access to this profile.

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.